Close Menu

NEW YORK (GenomeWeb) — IntegraGen announced today that it is collaborating with investigators from the FIRE-3 clinical trial to study the use of a microRNA biomarker to predict clinical outcomes in metastatic colorectal cancer patients treated with anti-EGFR therapies.

The FIRE-3 study is a Phase III trial comparing FOLFIRI — Camptosar (irinotecan) with fluorouracil and folinic acid — in combination with either Erbitux (cetuximab) or Avastin (bevacizumab) as a first-line therapy in patients with KRAS exon 2 wild-type stage IV colorectal cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.